Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arun A Azad

Showing results (51-60 of 140) with videos related to

Pageof 14
Sort By:
European Urology|February 11, 2014
Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance statusArun A Azad, Bernhard J Eigl, Raya Leibowitz-Amit, et al.
BJU International|April 14, 2026
Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancerAbdullah Al-Khanaty, David Chen, Jonathan Walbaum, et al.
European Urology|February 13, 2025
Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate CancerArun A Azad, Louise Kostos, Neeraj Agarwal, et al.
BJU International|July 25, 2015
Patterns of care for metastatic renal cell carcinoma in AustraliaDaphne Day, Yada Kanjanapan, Edmond Kwan, et al.
The Medical Journal of Australia|October 2, 2022
Modern paradigms for prostate cancer detection and managementIsabella Sc Williams, Aoife McVey, Sachin Perera, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|January 31, 2018
A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetateDaniel Joseph Khalaf, Claudia M Avilés, Arun A Azad, et al.
European Urology Focus|August 3, 2020
Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor-treated Metastatic Castration-resistant Prostate CancerHeidi Fettke, Edmond M Kwan, Patricia Bukczynska, et al.
The Prostate|September 2, 2014
A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancerArun A Azad, Raya Leibowitz-Amit, Bernhard J Eigl, et al.
Prostate Cancer and Prostatic Diseases|May 5, 2023
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancerTahlia Scheinberg, Hui-Ming Lin, Michael Fitzpatrick, et al.
JCO Clinical Cancer Informatics|July 25, 2023
Multi-Omic Integration of Blood-Based Tumor-Associated Genomic and Lipidomic Profiles Using Machine Learning Models in Metastatic Prostate CancerShikai Fang, Shandian Zhe, Hui-Ming Lin, et al.
Pageof 14

Showing results (51-60 of 140) with videos related to

Sort By:
Pageof 14
European Urology|February 11, 2014
Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance statusArun A Azad, Bernhard J Eigl, Raya Leibowitz-Amit, et al.
BJU International|April 14, 2026
Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancerAbdullah Al-Khanaty, David Chen, Jonathan Walbaum, et al.
European Urology|February 13, 2025
Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate CancerArun A Azad, Louise Kostos, Neeraj Agarwal, et al.
BJU International|July 25, 2015
Patterns of care for metastatic renal cell carcinoma in AustraliaDaphne Day, Yada Kanjanapan, Edmond Kwan, et al.
The Medical Journal of Australia|October 2, 2022
Modern paradigms for prostate cancer detection and managementIsabella Sc Williams, Aoife McVey, Sachin Perera, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|January 31, 2018
A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetateDaniel Joseph Khalaf, Claudia M Avilés, Arun A Azad, et al.
European Urology Focus|August 3, 2020
Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor-treated Metastatic Castration-resistant Prostate CancerHeidi Fettke, Edmond M Kwan, Patricia Bukczynska, et al.
The Prostate|September 2, 2014
A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancerArun A Azad, Raya Leibowitz-Amit, Bernhard J Eigl, et al.
Prostate Cancer and Prostatic Diseases|May 5, 2023
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancerTahlia Scheinberg, Hui-Ming Lin, Michael Fitzpatrick, et al.
JCO Clinical Cancer Informatics|July 25, 2023
Multi-Omic Integration of Blood-Based Tumor-Associated Genomic and Lipidomic Profiles Using Machine Learning Models in Metastatic Prostate CancerShikai Fang, Shandian Zhe, Hui-Ming Lin, et al.
Pageof 14